Evaluation of drug targeting strategies and liposomal trafficking

被引:31
作者
Oku, N
Tokudome, Y
Asai, T
Tsukada, H
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Dept Radiobiochem, Shizuoka 4228526, Japan
[2] Hamamatsu Photon KK, Cent Res Lab, Shizuoka, Japan
关键词
D O I
10.2174/1381612003398816
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Liposomes, that are biodegradable and essentially non-toxic, can encapsulate both hydrophilic and hydrophobic materials, and are utilized as drug carriers for drug delivery systems (DDS). Recent progress in gene technology provides a novel modality of therapy for various diseases with a variety of newly-developed cationic liposomes. Delivery of agents to the reticuloendothelial system (RES) is easily achieved since most conventional liposomes are trapped by the RES. For the purpose of delivery of agents to target organs other than RES, long-circulating liposomes have been developed by modifying the liposomal surface. Understanding of the in vivo dynamics of liposome-carried agents is required to evaluate the bioavailability of drugs encapsulated in liposomes. In this review, we focus on the in vivo trafficking of liposomes visualized by positron emission tomography (PET) and discuss the characteristics of liposomes that affect the targeting of drugs in vivo.
引用
收藏
页码:1669 / 1691
页数:23
相关论文
共 117 条
[21]  
Dieter P, 1997, ADV EXP MED BIOL, V407, P485
[22]  
DOI K, 1994, BIOL PHARM BULL, V17, P1414
[23]   Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells [J].
Düzgünes, N ;
Pretzer, E ;
Simoes, S ;
Slepushkin, V ;
Konopka, K ;
Flasher, D ;
de Lima, MCP .
MOLECULAR MEMBRANE BIOLOGY, 1999, 16 (01) :111-118
[24]   Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection [J].
Embree, L ;
Gelmon, K ;
Tolcher, A ;
Hudon, N ;
Heggie, J ;
Dedhar, C ;
Logan, P ;
Bally, MB ;
Mayer, LD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 41 (05) :347-352
[25]   Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir [J].
Fresta, M ;
Panico, AM ;
Bucolo, C ;
Giannavola, C ;
Puglisi, G .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1999, 51 (05) :565-576
[26]   CONTRIBUTION OF COMPLEMENT-SYSTEM ON DESTABILIZATION OF LIPOSOMES COMPOSED OF HYDROGENATED EGG PHOSPHATIDYLCHOLINE IN RAT FRESH PLASMA [J].
FUNATO, K ;
YODA, R ;
KIWADA, H .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1103 (02) :198-204
[27]   Development of liposomal anthracyclines: from basics to clinical applications [J].
Gabizon, A ;
Goren, D ;
Cohen, R ;
Barenholz, Y .
JOURNAL OF CONTROLLED RELEASE, 1998, 53 (1-3) :275-279
[28]  
Gregoriadis G., 1992, LIPOSOME TECHNOLOGY
[29]   Development of liposomal amphotericin B formulation [J].
Gulati, M ;
Bajad, S ;
Singh, S ;
Ferdous, AJ ;
Singh, M .
JOURNAL OF MICROENCAPSULATION, 1998, 15 (02) :137-151
[30]   ENHANCED HEPATIC-UPTAKE OF LIPOSOMES THROUGH COMPLEMENT ACTIVATION DEPENDING ON THE SIZE OF LIPOSOMES [J].
HARASHIMA, H ;
SAKATA, K ;
FUNATO, K ;
KIWADA, H .
PHARMACEUTICAL RESEARCH, 1994, 11 (03) :402-406